Vanda Pharmaceuticals To Be Primary Sponsor Of Schumacher’s INDYCAR Entry For Four Races; Schumacher to Pilot the No. 47 NEREUS™ Honda at events in Nashville, Portland, Washington D.C. and Monterey

ZIONSVILLE, Ind. (July 15, 2026) – Rahal Letterman Lanigan Racing (RLL) announced today that Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, will be the primary sponsor of Mick Schumacher’s No. 47 NTT INDYCAR SERIES entry at four series events in 2026.

Vanda Pharmaceuticals will feature NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion, on the No. 47 Honda for Mick Schumacher in events in Nashville, Portland, their home race in Washington D.C. and Monterey, Calif.

While this is the first involvement in motorsports for Vanda Pharmaceuticals, they are involved in other high-profile sports sponsorships across the ATP (venue), NHL, NBA, WNBA, college basketball, and regional sports networks to enhance brand visibility and community engagement.

Schumacher, the son of legendary seven-time Formula One champion, Michael Schumacher, is in the midst of his first season in INDYCAR competition. His impressive resume includes 43 Formula One starts and a best finish of sixth place, along with three podiums in World Endurance Championship (WEC) competition.

After 11 of 18 INDYCAR races in 2026, Schumacher’s best start is an impressive fourth — earned in his first-ever oval race at Phoenix in only his second series start — while his best finish of 16th came on the oval at World Wide Technology Raceway near St. Louis. He was named the 2026 Indy 500 Rookie of the Year and also won the Fastest Rookie award.

Despite seeing most tracks for the first time, and learning the new discipline of oval racing, Schumacher has shown promise and run at the front, most notably when he was in third place late in the Detroit street race before the loss of radio communication hindered his opportunities and he ultimately had to pit for mandatory repair due to safety reasons.

The 2026 NTT INDYCAR SERIES season resumes with the Borchetta Bourbon Music City Grand Prix, Round 12 of 18, on Sunday, July 19. Live coverage of the race begins at 5:30 p.m. on FOX, FOX Deportes, FOX One and the FOX Sports app. The 18-race schedule includes new venues in Arlington, Texas, Markham, Ontario, Canada and Washington, D.C. For more information about the series or team, visit www.indycar.com and www.rahal.com.

QUOTE BOARD:

MIHAEL POLYMEROPOULOS, M.D, CEO of Vanda Pharmaceuticals: “We are proud to partner with the historic RLL racing team featuring our launch of Nereus with the number 47 car driven by Mick Schumacher, which also celebrates 47 years since the last treatment approved in the United States for people with motion sickness.”

JAY FRYE, President of RLL: “We are proud to partner with a company that is committed to helping people optimize their health and live healthier, more active lives. We are especially excited to support this effort through their home race — the Freedom 250 Grand Prix of Washington, D.C., a unique platform that allows us to raise awareness of an important health solution while engaging with fans in a meaningful way.”

About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

About NEREUS™
NEREUS™ (tradipitant) is a neurokinin-1 receptor antagonist licensed by Vanda from Eli Lilly and Company. NEREUS™ is approved for the acute prevention of vomiting induced by motion in adults, and is currently in clinical development for a variety of indications, including gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this press release, including, but not limited to statements regarding Vanda’s further clinical development plans for NEREUS™, are “forward-looking statements” under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, Vanda’s ability to continue to advance tradipitant in gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized, or even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most recent Annual Report on Form 10-K, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.